Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.

"Declarations Conflict of interestMJM has research funding from TARGET PharmaSolutions, GlaxoSmithKline, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Genfit, Mirum, and Mallinckrodt; and consultation fees from TARGET PharmaSolutions, GlaxoSmithKline, CymaBay Pharmaceuticals, and Mallinckrodt. EC and WRK have no conflicts to report. HS and MM are employees of GlaxoSmithKline and hold stocks/shares in the company. AT was an employee of GSK at the time of the study and holds stocks/shares in the company. ARM, HLM, and RS are Target RWE employees. CB has research funding from Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, GlaxoSmithKline, BristolMyerSquibb, TARGET Pharmasolutions, Novartis, BiomX, Mirum, Genfit, Pliant, Cara Therapeutics, and Boston Scientific. CL has research funding from Gilead, Intercept, CymaBay, Genfit, GSK, Novartis, High Tide, Zydus, Cara Therapeutics, Mirum, Pliant, and Target PharmaSolutions; consultation fees from CymaBay, Genfit, GSK, Pliant, Mirum, Cara Therapeutics, Escient, Teva, Calliditas, and Intercept; royalties from Up-to-date; and is the Associate Editor for Hepatology, Member of the ABIM Test and Policy committee for transplant hepatology. Conflict of interest MJM has research funding from TARGET PharmaSolutions, GlaxoSmithKline, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Genfit, Mirum, and Mallinckrodt; and consultation fees from TARGET PharmaSolutions, GlaxoSmithKline, CymaBay Pharmaceuticals, and Mallinckrodt. EC and WRK have no conflicts to report. HS and MM are employees of GlaxoSmithKline and hold stocks/shares in the company. AT was an employee of GSK at the time of the study and holds stocks/shares in the company. ARM, HLM, and RS are Target RWE employees. CB has research funding from Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, GlaxoSmithKline, BristolMyerSquibb, TARGET Pharmasolutions, Novartis, BiomX, Mirum, Genfit, Pliant, Cara Therapeutics, and Boston Scientific. CL has research funding from Gilead, Intercept, CymaBay, Genfit, GSK, Novartis, High Tide, Zydus, Cara Therapeutics, Mirum, Pliant, and Target PharmaSolutions; consultation fees from CymaBay, Genfit, GSK, Pliant, Mirum, Cara Therapeutics, Escient, Teva, Calliditas, and Intercept; royalties from Up-to-date; and is the Associate Editor for Hepatology, Member of the ABIM Test and Policy committee for transplant hepatology."

"Funding This work was supported by Target RWE and analysis was funded by GSK (GSK study Number: 213259)."